Related stories
Nxera Pharma Licenses IBD Drug Candidate to AbbVie
Nxera will receive US$100 million upfront and is eligible for up to US$1.37 billion in development and other milestone payments under a global license agreement with AbbVie.
M impact | EQUITY | Nov 04, 2026, 08:46 AM UTC
Sundaram-Clayton Shares Rally 11.1% After September-Quarter Results
Shares reached an intraday high of ₹1,175.85, up ₹117.55 or 11.1%, after the company reported sharply higher revenue and a narrower net loss year over year.
M impact | EQUITY | Nov 04, 2026, 08:41 AM UTC
Turkey’s BIST-100 index extends gains, up 3%
M impact | EQUITY | Nov 04, 2026, 08:41 AM UTC
Hecla Mining Reports Q3 Earnings and Revenue Rise
Hecla Mining reported Q3 earnings of $0.22 per share. The supplied report says revenue rose.
M impact | EQUITY | Nov 04, 2026, 08:40 AM UTC
Memrayvity to Acquire Convertible Bonds Before Maturity
Memrayvity decided on Nov. 4, 2026, to acquire its 13th convertible bonds before maturity at the bondholder’s request.
M impact | EQUITY | Nov 04, 2026, 08:39 AM UTC
Shanghai Pharmaceuticals Controlling Shareholder Plans H-Share Purchase
Shanghai Pharmaceuticals said its controlling shareholder plans to increase its holdings of the company’s H shares.
M impact | EQUITY | Nov 04, 2026, 08:39 AM UTC